The use of ultrasound (US) to assist in liver biopsy for nonfocal @entity409 has been shown to significantly decrease the incidence of @entity532 ( @entity158 requiring treatment, @entity551 , or @entity548 ). In this study, decision analysis was used to estimate the average additional net charge for US guidance. The risks for minor and major complications were extracted from the literature. The incidence of @entity532 such as @entity158 and @entity548 not requiring hospitalization has been reported as 49% for blind liver biopsy and 39% for US-guided liver biopsy. Major complications requiring hospital admission occur in 4% of blind liver biopsies and 2% of US-guided liver biopsies. A decision tree was used to calculate the total charges of liver biopsy and its associated complications. The charge for treating an episode of @entity532 was estimated at  605. The charge related to an episode of major complications was estimated at  1533. The total charge for an ultrasound-guided liver biopsy (except the added charge for the use of ultrasound) was  1770, or  102 less than the same charge for blind liver biopsy. The addition of ultrasound in performing liver biopsies for @entity409 is cost-saving if the additional charge of US is less than  102.

Ultrasound-guided liver biopsy for XXXX : an economic analysis.

@entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity409 :: ('MESH:D008107', 'Disease') :: ['diffuse parenchymal liver disease', 'liver disease'] @entity532 :: ('MESH:D003925', 'Disease') :: ['minor complications'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'defined as pain'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']
@entity409 :: (MESH:D008107,Disease) :: ['parenchymal liver disease']
